Nautilus Biotechnology Inc

Latest Report Overview

Nautilus Biotechnology Inc (NAUT) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $190 thousand with diluted EPS of $-0.11 and net income of -$14.5 million. Operating margin was -8296.3%, and free cash flow was -$14.2 million for the period. During the second quarter of fiscal 2026, Nautilus advanced the operational and technical transition of its proprietary single-molecule proteome analysis platform toward commercial availability. Operating expenditures were led by research and development investments of $9.31 million, compared to $9.41 million in the first quarter of fiscal 2026 and $9.99 million in the year-ago quarter, as engineering teams focused on optimizing optical imaging precision, nanofabricated array yields, and multi-affinity probe libraries. Selling, general, and administrative expenses supported pre-commercial operational infrastructure and customer engagement preparations. Management highlighted that inaugural revenue reflects initial pilot evaluation studies and early-access customer service collaborations with academic and biopharmaceutical researchers. The primary operational focus remains centered on verifying platform reproducibility, enhancing consumable flow cell manufacturing, and refining algorithmic decoding models that translate iterative optical binding cycles into intact protein identifications across high dynamic ranges. From a liquidity perspective, Nautilus closed the quarter with $13.17 million in cash and cash equivalents following an operating cash burn of $13.73 million and free cash flow of -$14.18 million. With no long-term funded debt on the balance sheet, management is actively managing operating cash outlays while assessing strategic financing avenues, collaborative partnerships, and capital structure options to support commercial scale-up and ongoing corporate operations.

Key Takeaways for Nautilus Biotechnology Inc

• First commercial revenue generation: Nautilus reported its first commercial revenue of $190,000 for the quarterly period ended June 30, 2026, marking an initial transition from pre-revenue technology development to early customer evaluation services.
• Persistent net losses and cash burn: The company recorded a net loss of $14.47 million and a diluted EPS of -$0.11 in Q2 2026, driven by sustained development and pre-commercial operational expenditures.
• Critical cash runway depletion: Cash and cash equivalents declined to $13.17 million as of June 30, 2026, compared to a quarterly operating cash burn of $13.73 million and free cash flow of -$14.18 million, necessitating imminent external capital raising or partnership funding.
• Targeted R&D deployment: Research and development expenditures totaled $9.31 million in Q2 2026, reflecting continuous investment in consumable nanofabricated chips, optical hardware calibration, and machine-learning decoding software.
• Debt-free balance sheet: Nautilus maintains a capital structure with $0.00 in funded debt, leaving the business unencumbered by interest expenses as it navigates early commercialization.
• Incumbent competitive dynamics: Nautilus faces entrenched competition from mass spectrometry leaders like Thermo Fisher Scientific and Bruker, requiring demonstrable proof of superior proteome coverage and single-molecule resolution to drive instrument adoption.

What Does Nautilus Biotechnology Inc Do?

Nautilus Biotechnology, Inc. is a development-stage life sciences technology company focused on transforming the field of proteomics through the creation and commercialization of an ultra-sensitive, single-molecule proteome analysis platform. The proprietary platform integrates high-density nanofabricated silicon chips featuring billions of individual landing pads for single protein molecules, repetitive probing using short, fluorescently labeled multi-affinity protein-directed reagents, and high-resolution optical imaging coupled with advanced machine-learning decoding software. This architecture is designed to enable the comprehensive quantification and identification of intact proteins across a wide dynamic range, overcoming the sensitivity, dynamic range, and throughput limitations inherent in traditional mass spectrometry and affinity-based multiplex assays. The company targets enterprise and institutional customers across biopharmaceutical companies, academic research institutions, contract research organizations, and clinical research centers globally. The platform is initially oriented toward Research Use Only (RUO) applications, supporting basic biological discovery, disease biomarker validation, drug target identification, and translational research. By aiming to measure substantially all expressed proteins in complex biological samples at single-molecule resolution, Nautilus seeks to unlock an estimated total addressable proteomics market exceeding $25 billion. Headquartered in Seattle, Washington, with specialized biochemistry and hardware engineering facilities in San Carlos, California, Nautilus employs approximately 100 to 150 multidisciplinary scientists, optical engineers, and computational biologists. The business model is differentiated by its non-destructive, single-molecule nanoarray design and iterative multi-affinity probing methodology, which does not require enzymatic peptide digestion or a bespoke high-affinity antibody for every single target protein, enabling comprehensive characterization of intact proteoforms.

Growth Drivers for Nautilus Biotechnology Inc

• Broad commercial release and placement of the Nautilus proteome analysis instrument across academic core facilities and biopharmaceutical discovery laboratories.
• Expansion of recurring consumable revenue driven by annual pull-through of proprietary nanofabricated flow cells and multi-affinity reagent kits per placed instrument.
• Execution of early-access collaborative research and pilot biomarker discovery services with tier-one biopharmaceutical companies.
• Scaling the multi-affinity probe library and refining machine-learning algorithms to expand the depth, dynamic range, and speed of intact protein identification.
• Establishment of a dedicated direct commercial sales, customer support, and field application team across major North American and European life sciences hubs.
• Expansion into clinical translational research, diagnostic biomarker validation, and therapeutic monitoring applications.